Speakers:
– Susan Cantrell, Chief Executive Officer, Academy of Managed Care Pharmacy
– Megan Coder, Executive Director, Digital Therapeutics Alliance
– Laura Topor, President, Granada Health and Former NCPDP Trustee

Moderator:
– Claire Wulf Winiarek, Vice President of Policy, PCMA

Speakers:
– Tom Peddicord, Head National Accounts Population, Health MSL Team, U.S. Pharma HE&OR and Medical Access, Novartis Pharmaceuticals Corp
– Brett Sahli, Senior Director, Value and Outcomes, Prime Therapeutics

Moderator:
– Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips

Although the COVID-19 vaccine rollout has had a successful start, major health inequities still exist in vaccine access for underserved communities and underrepresented minorities. Between 2 and 3 million Americans are being vaccinated a day, but disproportionately fewer of those vaccinated are in communities of color and other underrepresented communities. Discuss the unique social determinants of why these inequities exist, why it’s important to reframe COVID-19 vaccination campaigns for specific communities, and how health care stakeholders, including physicians and PBMs, are working to educate underserved populations on the safety and efficacy of COVID-19 vaccines.

Speakers:
– Dr. Sree Chaguturu, Senior Vice President & Chief Medical Officer, CVS Caremark
– Dr. Elena Rios, President and Chief Executive Officer, National Hispanic Medical Association

Moderator:
– Claire Wulf Winiarek, Vice President of Policy, PCMA

Biopharmaceutical innovation continues to deliver groundbreaking rare disease, curative, and personalized gene therapies to meet unmet patient medical needs. While these new advancements, such as orphan and gene therapies, offer new hope, they also represent a significant challenge of affordability. The health care system will require additional tools and collaboration to ensure appropriate therapy access and predictable affordability. This session will discuss industry trends and priorities, areas of payment and pharmaceutical care management innovation, and opportunities to find common ground to address these unique challenges across the health care ecosystem – essential  to maintaining and supporting biopharmaceutical innovation and access in the future.

Speaker:
– Matt Perlberg, Senior Vice President, Supply Chain, Express Scripts

Moderator:
– Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips

In 2019, specialty drugs accounted for 48.5 percent of net cost in Medicaid while making up just 1.3 percent of utilization. Unit cost – not utilization, which fell – drove Medicaid specialty trend, with net cost per claim increasing by $141.12. States and their Medicaid programs are facing stark challenges when it comes to the affordability of these high-cost drugs. This session will review the prior administration’s efforts related to Medicaid waivers, specifically the waiver requested by the state of Tennessee, which included a closed formulary, and the potential mechanisms to innovate Medicaid prescription drug coverage through additional commercial-like tools.

Speakers:
– Ross Margulies, Partner, Foley Hoag
– Matt Salo, Executive Director, National Association of Medicaid Directors

Moderator:
– Debjani Mukherjee, Senior Director, Regulatory Affairs, PCMA

Since the launch of Medicare’s prescription drug benefit in 2006, Part D plan sponsors have been central to advancing health care outcomes for Medicare beneficiaries. This session will focus on the Part D program, highlighting targeted and comprehensive clinical care programs offered by plan sponsors, and innovative programs developed in partnership with the Center for Medicare and Medicaid Innovation (CMMI) such as the Senior Savings Demonstration Model aimed at improving medication adherence through capping beneficiary out-of-pocket costs for insulin.

Speaker:
– Bethanie Stein, President of PBM Services, Humana Inc.

Moderator:
– Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips

Biosimilar approval and marketing of products in the United States had been proceeding at a slower pace than desired by many stakeholders but has picked up significantly. Our speakers will discuss the importance of competition for biologics and biosimilars “coming of age” in the United States, as well as recent and expected future developments in the market. Additionally they will explain how PBMs are supporting biosimilar adoption, the movement from medical benefit to drug benefit for coverage of biosimilars, how payers are working with PBMs to advance access to biosimilars, and the role of patient and provider education.

Speakers:
– Deedrea Grein, Senior Vice President, Product, OptumRx
– Michael Zeglinski, Senior Vice President and Chief Executive Officer, Specialty Infusion Pharmacy, OptumRx

The overall drug pipeline disproportionately reflects specialty drugs, which showcase promising pharmaceutical innovation for patients, but often come with high costs. Value based arrangements (VBA) are gaining traction in the market thanks to a number of factors including aligned incentives and access to better data. This session features a panel discussion on why the oncology and rare disease categories are ideal for VBAs, and how PBMs and biopharmaceutical companies are innovating to structure collaborative arrangements that support patient access, affordability, and care management to improved health outcomes.

Speakers:
– Adam Kautzner, Chief Pharma Trade Relations Officer, Express Scripts
– Gary Loeber, Executive Vice President of Pharmaceutical Contracting and Purchasing, CVS
– Patrick Moss, Vice President of Specialty Distribution & Payer Access, Sarepta Therapeutics
– Jen Norton, Vice President and Head of U.S. Value & Access, Amgen

Moderator:
– Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips

When PBM’s and providers are digitally connected, patient and provider abrasion are reduced. Giving providers actionable information within their EMR workflow is paramount to effectively partnering with them to close gaps in care. IngenioRx uses digital functionality with providers for pharmacy insights, electronic prescribing, real time pharmacy benefits and electronic prior authorization to help reduce disruption for both the provider and patient member. This session will highlight how PBMs like IngenioRx are leveraging technology to provide improved clinical care to patients, and a look into the adoption and utilization of these technologies.

Speaker:
– Jacquelyn Vondrak, Staff Vice President of Clinical Pharmacy Services, IngenioRx

Moderator:
– Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips